Navigation Links
GenScript Announces Joint Road Show with Open Monoclonal Technology, Inc.

PISCATAWAY, N.J., Jan. 22, 2013 /PRNewswire/ -- GenScript and Open Monoclonal Technology, Inc. (OMT) today announced a joint road show with potential clients across the US, China, Japan and South Korea in late January and early February. The road show will offer prospective clients introductions to GenScript and OMT's human antibody discovery technologies and explore new ways of accelerated and improved development of this important class of human therapeutics.


GenScript offers a full spectrum of human antibody services, including target screening and expression, immunization, monoclonal antibody screening at any desired high complexity, antibody sequencing and characterization, biological and other assays, antibody production cell line development, model animal-based efficacy studies and more. GenScript's antibody development team consists of senior scientists and business managers who have extensive experience in therapeutic antibody development. They have been involved in the full process of therapeutic drug development. GenScript has already successfully gained a top position in gene synthesis worldwide, and has established leading positions in many other biology service areas.

Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for the development of human therapeutic antibodies – naturally optimized human antibodies™. OMT has created OmniRat™, the first fully human monoclonal antibody platform based on transgenic rats. OmniRat™ uses an improved understanding of B cell development and a new approach to inactivation of endogenous antibody expression, which enables them to make antibodies with human idiotypes as efficiently as wild type rats make normal antibodies. OmniRat™ represents a novel and proprietary technology with unrestricted development options for fully human monoclonal antibodies, available worldwide for all targets and indications. OMT also develops a transgenic mouse, OmniMouse™, to complement OmniRat™ and further increase epitope coverage in human antibody development. OmniAb™ integrates OMT's transgenic animal platforms, proven protein- and DNA-mediated immunization and Gel-Encapsulated Microenvironment (GEM) deep antibody screening to enable fast and cost-efficient generation and identification of preferred human therapeutic antibody candidates.

Web site:


SOURCE GenScript USA Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GenScript anuncia un programa conjunto con Open Monoclonal Technology, Inc.
2. GenScript kündigt gemeinsame Roadshow mit Open Monoclonal Technology, Inc. an
3. GenScript anuncia una muestra itinerante conjunta con Open Monoclonal Technology, Inc.
4. GenScript Anuncia Exposição Itinerante Junto com a Open Monoclonal Technology, Inc.
5. TNI BioTech, Inc. Announces Appointment of New CFO
6. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
7. BioDelivery Sciences Announces Completion of BNX Safety Study
8. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
9. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
10. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
11. Ampio Pharmaceuticals Announces Participation at Upcoming Investor Conference
Post Your Comments:
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary ... Periwinkle Pioneers, nominated by the public, will receive special recognition throughout 2016 as ...
Breaking Medicine News(10 mins):